Business Context and Reporting Period
Inmune Bio, Inc. (INMB), a Nevada corporation and emerging growth company, filed this Form 8-K on July 13, 2021. The report details the entry into a material definitive agreement for a registered direct offering of common stock.
Key Financial Metrics and Transaction Details
- Transaction Type: Registered direct offering of common stock.
- Shares Issued: 1,818,182 shares.
- Price Per Share: $22.00.
- Gross Proceeds: Approximately $40,000,000.
- Placement Agent: A.G.P./Alliance Global Partners (AGP).
- Placement Fees: 6.0% cash fee of gross proceeds, with a 1.0% credit to the Company.
- Other Expenses: Company to pay all offering expenses, including legal fees for AGP not exceeding $35,000.
The filing does not provide specific data on revenue, profit, operating cash flow, margins, or existing debt levels, as this is a current report regarding a specific financing event rather than a periodic financial statement.
Material Changes and Outlook
The primary material change is the anticipated increase in liquidity through the sale of equity. The offering is expected to close on or about July 16, 2021, subject to customary closing conditions. The shares are being issued pursuant to a Prospectus Supplement filed under the Company's effective Form S-3 Registration Statement (No. 333-254221).
Management Commentary and Risks
Management engaged AGP as the sole placement agent to facilitate the offering. The Company has received a legal opinion from Sichenzia Ross Ference LLP regarding the validity of the securities. No specific risks, contingencies, or unusual items beyond the standard closing conditions of the offering are detailed in this specific filing text.
Investor Verification Checklist
- Verify the final closing date of the offering (expected July 16, 2021).
- Confirm the net proceeds after deducting the 5.0% net placement fee and other offering expenses.
- Review the full Prospectus Supplement (Exhibit 99.1 press release and related filings) for use of proceeds.
- Check for any over-allotment options or additional terms in the Securities Purchase Agreement (Exhibit 10.1).